Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.
It is not known whether patients with anti-epiligrin cicatricial pemphigoid (AECP) have an increased risk of malignancy. We calculated the expected numbers of cancers in a cohort of 35 such patients based on respective incidence rates for all cancers in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Ten patients in this cohort had solitary solid cancers; eight patients developed cancer after onset of AECP (seven within 14 months). The relative risk (RR) for cancer in this cohort was 6.8 (95% confidence intervals [CI]: 3.3-12.5). AECP seems to be associated with an increased relative risk for cancer.
Egan
C A
CA
Lazarova
Z
Z
Darling
T N
TN
Yee
C
C
Coté
T
T
Yancey
K B
KB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D002423:Cause of Death; D015815:Cell Adhesion Molecules / Q000276:immunology*; D015331:Cohort Studies; D004198:Disease Susceptibility; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality*; D010390:Pemphigoid, Benign Mucous Membrane / Q000276:immunology / Q000401:mortality*; D012306:Risk; D016019:Survival Analysis; D000097794:Kalinin
D001323:Autoantibodies; D015815:Cell Adhesion Molecules; D000097794:Kalinin